Teva announces $2,250,000,000 debt tender offers for notes due 2023-2026

Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) (“teva”) announced today that it has commenced tender offers (the “offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,250,000,000 (the “total maximum amount”) of the following series of notes issued by finance subsidiaries of teva and guaranteed by teva: 7.
TEVA Ratings Summary
TEVA Quant Ranking